GetTopicDetailResponse(id=376e2818141, topicName=兒童低級別膠質(zhì)瘤, introduction=兒童低級別膠質(zhì)瘤, content=null, image=null, comments=2, allHits=1596, url=https://h5.medsci.cn/topic?id=28181, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=55268, tagList=[TagDto(tagId=55268, tagName=兒童低級別膠質(zhì)瘤)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2175328, encodeId=c5f621e5328e2, content=<a href='/topic/show?id=376e2818141' target=_blank style='color:#2F92EE;'>#兒童低級別膠質(zhì)瘤#</a> 兒童低級別膠質(zhì)瘤（pLGG）是兒童中最常見的中樞神經(jīng)系統(tǒng)腫瘤，約占所有兒童腦腫瘤的30%。目前的治療包括手術切除、化療和MEK抑制劑，但對于復發(fā)或難以手術切除的病例，治療選擇有限。Tovorafenib是由Day One Biopharmaceuticals公司開發(fā)的新型RAF抑制劑，主要用于治療BRAF基因改變的復發(fā)/難治性兒童低級別膠質(zhì)瘤（pLGG）。, objectTitle=兒童低級別膠質(zhì)瘤, objectType=topic, longId=28181, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=78, createdTime=2023-12-16, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=浙江省, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2175468, encodeId=08eb21e54687f, content=<a href='/topic/show?id=d3b326916c3' target=_blank style='color:#2F92EE;'>#依維莫司#</a> <a href='/topic/show?id=376e2818141' target=_blank style='color:#2F92EE;'>#兒童低級別膠質(zhì)瘤#</a>, objectTitle=JCO：依維莫司在復發(fā)或進展性兒童低級別膠質(zhì)瘤中呈現(xiàn)療效！, objectType=article, longId=804496, objectId=10ae804496b0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medics-and-patient-on-hospital-gurney-at-PMW6NAQ.jpg, objectUrl=/article/show_article.do?id=10ae804496b0, replyNumber=0, likeNumber=101, createdTime=2023-12-17, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=10ae804496b0, moduleTitle=JCO：依維莫司在復發(fā)或進展性兒童低級別膠質(zhì)瘤中呈現(xiàn)療效！, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=10ae804496b0)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2175291, encodeId=affe21e529186, content=<a href='/topic/show?id=b8b82229451' target=_blank style='color:#2F92EE;'>#中樞神經(jīng)系統(tǒng)腫瘤#</a> <a href='/topic/show?id=376e2818141' target=_blank style='color:#2F92EE;'>#兒童低級別膠質(zhì)瘤#</a> <a href='/topic/show?id=b8bc108640e3' target=_blank style='color:#2F92EE;'>#Tovorafenib#</a>, objectTitle=Nature Medicine：Tovorafenib為治療兒童低級別膠質(zhì)瘤帶來新希望, objectType=article, longId=804358, objectId=3903804358ff, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230326/1679866876965_4754896.webp, objectUrl=/article/show_article.do?id=3903804358ff, replyNumber=0, likeNumber=151, createdTime=2023-12-16, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=3903804358ff, moduleTitle=Nature Medicine：Tovorafenib為治療兒童低級別膠質(zhì)瘤帶來新希望, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=3903804358ff)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=943879, encodeId=4c459438e9c0, content=<a href='/topic/show?id=376e2818141' target=_blank style='color:#2F92EE;'>#兒童低級別膠質(zhì)瘤#</a>兒童低級別膠質(zhì)瘤不容忽視。, objectTitle=兒童低級別膠質(zhì)瘤, objectType=topic, longId=28181, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=129, createdTime=2021-02-27, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
關注
已關注
2020-05-29
前往app查看評論內(nèi)容
全文
收起
#兒童低級別膠質(zhì)瘤# 兒童低級別膠質(zhì)瘤（pLGG）是兒童中最常見的中樞神經(jīng)系統(tǒng)腫瘤，約占所有兒童腦腫瘤的30%。目前的治療包括手術切除、化療和MEK抑制劑，但對于復發(fā)或難以手術切除的病例，治療選擇有限。Tovorafenib是由Day One Biopharmaceuticals公司開發(fā)的新型RAF抑制劑，主要用于治療BRAF基因改變的復發(fā)/難治性兒童低級別膠質(zhì)瘤（pLGG）。
